--- title: "भारतात GLP-1 थेरेपी साठी कौन पात्र?" description: "BMI thresholds, comorbidities, thin-fat phenotype, वैद्य काय evaluate करता।. Medically reviewed, CDSCO-aware guides for Indian patients. Kesho does not…" canonical: "https://www.kesho.health/mr/blog/who-qualifies-glp-1-india" markdown_url: "https://www.kesho.health/md/mr/blog/who-qualifies-glp-1-india" date_published: "Jun 15, 2026" date_modified: "Jun 26, 2026" author: "Dr. Ananya Mehta" language: "mr-IN" primary_keyword: "GLP-1 eligibility India" --- # भारतात GLP-1 थेरेपी साठी कौन पात्र? > **Short answer:** RSSDI: T2D first-line अपर्याप्त। Obesity: BMI ≥27.5 या ≥25 comorbidity ICMR। Lifestyle trial पहले। Physician contraindications, affordability, monitoring—Kesho पात्रता नाही तय करता। Labs, waist, lifestyle docs लाएँ। **Canonical HTML:** https://www.kesho.health/mr/blog/who-qualifies-glp-1-india **Markdown:** https://www.kesho.health/md/mr/blog/who-qualifies-glp-1-india *Eligibility साधारण BMI checklist नाही. ICMR/RSSDI South Asian thin-fat, central obesity, early diabetes family history। Criteria समझकर consultation तैयार, decline क्यों, self-diagnose/unregulated sellers नाही. Scale से documentation/honest lifestyle इतिहास।* *Reviewed by Dr. Ananya Mehta, MD, DM Endocrinology. This article has been reviewed by our medical advisory team, including endocrinologists, internal medicine specialists, and cardiologists, and is based on current scientific evidence and Indian clinical guidelines. Last reviewed: June 2026.* ## Key takeaways - T2D indication high BMI not required—RSSDI HbA1c unmet despite metformin/lifestyle GLP-1 RA support। - Obesity ICMR BMI ≥27.5 या ≥25 comorbidity—Western ≥30 से lower। - Waist (>90 cm men, >80 cm women) thin-fat phenotype BMI जितना matter South Asian। - Contraindications pregnancy, MTC/MEN2, severe pancreatitis—CDSCO labels BMI regardless। - Obesity pharmacotherapy से पहले 3–6 months lifestyle; GLP-1 cosmetic shortcut never। ## At a glance (India) | Field | Value | | --- | --- | | Obesity BMI threshold (no comorbidity) | ≥27.5 kg/m² (ICMR-aligned) | | Obesity BMI with comorbidity | ≥25 kg/m² | | Waist risk (South Asian men / women) | >90 cm / >80 cm | | Typical diabetes HbA1c trigger | >7–7.5% despite first-line care | | Lifestyle trial before obesity Rx | Usually 3–6 months | | Prescription requirement | Schedule H; CDSCO-approved products | ## In this article - Type 2 diabetes indications - Obesity and weight criteria - Indian BMI thresholds explained - Comorbidities that matter - Who may not qualify - Assessment workflow - Family history and risk - If you were declined - Self-assessment mistakes - Preparing for your assessment - Sleep apnoea and metabolic syndrome - Prediabetes pathway in India - Employer wellness programmes - Documentation for insurance appeals - Re-evaluation timelines ## T2D मध्ये GLP-1 therapy कौन qualify? RSSDI lifestyle/metformin glycaemic targets fail—HbA1c >7–7.5% optimised care। CVD, heart failure, CKD, obesity, sulfonylurea hypoglycaemia favour। No single BMI diabetes; lean Indian T2D CVR/renal profile GLP-1। Age, kidney, concurrent meds selection। T1D, gestational without specialist, DKA not indicated। Diabetologist/endocrinologist HbA1c trends, glucose, complications before class। Schedule H prescription clinical criteria meet हों या न हों—always required। ## India obesity criteria GLP-1? ICMR/South Asia protocols BMI ≥27.5 no comorbidity medication consider, ≥25 comorbidity present। Below Western ≥30—Indians lower weights insulin resistance, fatty liver, CVR। Waist >90 men >80 women South Asians supplements BMI। Never first-line—3–6 months structured lifestyle first। Motivation, mental health, eating disorder, afford long-term assess। Cosmetic without metabolic not appropriate। BMI meet no lifestyle attempt—defer dietitian referral। ### Thin-fat phenotype South Asians common: apparently normal BMI high visceral fat low muscle—early metabolic disease। ## Indian BMI thresholds Western से क्यों अलग? Asian Indian phenotype Joshi et al.—higher visceral adiposity, insulin resistance, earlier T2D same BMI Caucasian। Chennai BMI 26 waist 92 cm > European BMI 28 metabolic risk। RSSDI/ICMR realities। Clinical judgement: marathon vegetarian BMI 27 no comorbidity vs sedentary executive BMI 27 prediabetes fatty liver different। Genetics, family, socioeconomic individual beyond population guidelines। WHO Asian BMI; ICMR most relevant patients। ### BMI thresholds: Western vs India-aligned - संदर्भ: Pharmacotherapy no comorbidity — Western: Often BMI ≥30 — India: Often BMI ≥27.5 (ICMR) - संदर्भ: With comorbidity — Western: Often ≥27 — India: Often ≥25 with comorbidity - संदर्भ: Waist focus — Western: Less — India: Central obesity central - संदर्भ: Lifestyle first — Western: Recommended — India: Required 3–6 months (ICMR) - संदर्भ: T2D indication — Western: Glycaemic — India: RSSDI after metformin uncontrolled ### Common comorbidities earlier GLP-1 (BMI ≥25) - Comorbidity: Prediabetes/elevated HbA1c — क्यों: Diabetes progression reduce; insulin sensitivity - Comorbidity: Hypertension — Weight/glycaemic BP support - Comorbidity: Dyslipidaemia — GLP-1 RA triglycerides/weight lipids improve - Comorbidity: NAFLD/fatty liver — 5–10% weight hepatic steatosis reduce - Comorbidity: Obstructive sleep apnoea — Weight apnoea severity improve - Comorbidity: Established CVD — RSSDI high-risk diabetes GLP-1 favour ## Comorbidities case strengthen GLP-1? BMI beyond metabolic clustering weigh। Prediabetes central obesity, multi-agent hypertension, high triglycerides, NAFLD ultrasound, sleep apnoea lifestyle insufficient pharmacotherapy justify। PCOS insulin resistance endocrine discussion। Premature CVD/diabetes family borderline numbers risk framing। RSSDI CVR integration diabetes+heart disease algorithm earlier isolated mild obesity। Labs/imaging document not self-report। ICMR obesity chronic disease complications not cosmetic। ## कौन qualify नाही/specialist review? Contraindications pregnancy/breastfeeding; MTC/MEN2; severe pancreatitis। Caution severe gastroparesis, active IBD, frail elderly low BMI harmful weight loss। Untreated eating disorders psychiatric before appetite suppressants। Cannot monitor/afford sustained counsel alternatives। First-degree thyroid cancer careful endocrine eval। Kesho eligibility नाही—physician full history/exam/investigations only। CDSCO label contraindications legally binding BMI regardless। ## Frequently asked questions ### Do I qualify for GLP-1 if my BMI is 24? BMI alone below 25 rarely supports obesity indication unless significant comorbidities and central obesity exist—waist above South Asian cut-offs may still prompt discussion at 25+ with metabolic risk. Type 2 diabetes indication does not require high BMI; RSSDI supports GLP-1 RAs for uncontrolled glycaemia after first-line therapy. Your doctor assesses the full clinical picture including labs, family history, and prior lifestyle attempts. Document waist circumference, prediabetes labs, and fatty liver imaging if available to strengthen borderline cases. ### Can teenagers get GLP-1 in India? Paediatric obesity management requires specialist care. Some GLP-1 RAs have limited adolescent approvals globally; Indian practice varies. A paediatric endocrinologist must guide any decision. ### Does prediabetes alone qualify me? Prediabetes with BMI ≥25 and other risk factors may support obesity pharmacotherapy discussion after lifestyle trial per ICMR guidance. Lifestyle intervention remains first-line—structured diet and activity records strengthen your case at reassessment. Medication decisions are individualised; prediabetes alone at BMI 23 without comorbidities rarely justifies GLP-1 initiation. ### I have PCOS—am I eligible? PCOS with insulin resistance and elevated BMI often prompts GLP-1 discussion for weight and metabolic benefits. Gynaecologist and endocrinologist collaboration is recommended when fertility goals, contraception, and glucose targets intersect. PCOS alone without meeting BMI or comorbidity thresholds may not justify pharmacotherapy—lifestyle and hormonal management remain foundational per standard Indian practice. ### Can I get GLP-1 only for cosmetic weight loss? Ethical prescribing targets health-related obesity with comorbidity risk, not cosmetic goals alone per ICMR frameworks. Doctors may decline when BMI, waist, and metabolic risk do not meet criteria—even if social pressure or event deadlines create urgency. Pharmacotherapy without medical indication exposes you to unnecessary side effects and cost. Focus on documented health markers and lifestyle records rather than appearance targets alone when discussing eligibility. ### Does a normal HbA1c disqualify me? For diabetes indication, inadequate glycaemic control is usually required—normal HbA1c suggests diabetes-specific indication may not apply unless other factors warrant continued review. For obesity indication, HbA1c may be normal while waist circumference, fatty liver, or prediabetes still support pharmacotherapy discussion per ICMR. Criteria depend on the treatment goal your doctor is addressing; bring full labs, not BMI alone. ### How long must I try lifestyle changes before GLP-1 for obesity? ICMR guidance typically expects structured lifestyle intervention over three to six months before obesity pharmacotherapy, documented with weight, diet, and activity records. Type 2 diabetes pathways may intensify earlier when HbA1c remains above target despite metformin and lifestyle per RSSDI. Your doctor will clarify which pathway applies to your case. ### Does fatty liver alone qualify me for GLP-1? NAFLD strengthens obesity pharmacotherapy discussion when combined with BMI ≥25 and other metabolic risk after lifestyle trial. Fatty liver at BMI below twenty-five without diabetes typically requires individual specialist assessment—not automatic GLP-1 indication. ### Can I qualify if I already take metformin? Metformin use is common and compatible with GLP-1 initiation for type 2 diabetes when HbA1c remains above target. For obesity-only indication, metformin alone does not replace BMI and lifestyle criteria. Bring current metformin dose and glucose response data to your assessment. ### How does hypothyroidism affect GLP-1 eligibility? Hypothyroidism itself is not a contraindication if adequately treated—optimise thyroid hormone replacement before obesity or diabetes pharmacotherapy decisions. Untreated hypothyroidism can elevate weight and lipids, confounding eligibility assessment. Personal or family medullary thyroid carcinoma history is a separate contraindication from common hypothyroidism. Bring recent thyroid labs and medication doses to your specialist visit. ### Can I qualify with normal blood pressure and lipids? Yes for obesity pathway if BMI and lifestyle trial criteria are met—comorbidities strengthen but are not always mandatory at BMI ≥27.5. Diabetes pathway focuses on HbA1c and RSSDI cardiovascular criteria. Bring full metabolic labs, not BMI alone, to specialist assessment. Document prior dietitian or structured programme attendance when available. ## People also ask ### Can I get GLP-1 with BMI 23 if I have fatty liver? BMI alone below 25 rarely supports obesity pharmacotherapy. However, type 2 diabetes or prediabetes pathways may still apply if glycaemic criteria are met. Fatty liver with central obesity and strong metabolic risk may prompt discussion at BMI 25+ with comorbidities. Only your doctor can decide after full workup. ### Do I need a diabetes diagnosis to qualify? Not always. GLP-1 RAs are used for obesity in eligible adults without diabetes when ICMR BMI and comorbidity criteria are met after lifestyle trial. Conversely, type 2 diabetes patients may qualify without high BMI based on RSSDI glycaemic and cardiovascular criteria. ### Will my doctor prescribe GLP-1 for PCOS? PCOS with insulin resistance, elevated BMI, and metabolic risk often leads to GLP-1 discussion. Gynaecologist and endocrinologist collaboration is recommended. PCOS alone without meeting weight or glucose criteria may not justify pharmacotherapy. ### Can I qualify if I am prediabetic only? Prediabetes with BMI ≥25 and additional risk factors may support obesity pharmacotherapy discussion per ICMR frameworks. Lifestyle intervention remains first-line. Medication is individualised—not automatic for prediabetes alone. ### Does age affect GLP-1 eligibility in India? Adults are the primary population in CDSCO-approved labelling. Elderly frail patients with low BMI may be poor candidates due to unintended weight loss. Paediatric use requires specialist paediatric endocrinology—never adult telehealth shortcuts. ### What if my HbA1c is already normal? For obesity indication, normal HbA1c does not disqualify you if BMI and comorbidity criteria are met. For diabetes indication, inadequate glycaemic control is typically required—normal HbA1c suggests diabetes indication may not apply. ### Can corporate wellness programmes guarantee GLP-1 access? No ethical programme guarantees prescriptions. Eligibility requires medical evaluation, contraindication screening, and often documentation of prior lifestyle attempts for obesity indications. Avoid platforms promising automatic approval. ### How does kidney disease affect qualification? Mild to moderate kidney disease does not automatically exclude GLP-1 RAs and may favour them in diabetes with CKD per RSSDI. Severe renal impairment requires specialist dosing review. Bring recent creatinine and eGFR results to your appointment. ### I had bariatric surgery—can I still use GLP-1? Some post-bariatric patients with weight regain or recurrent diabetes may be candidates, but anatomy, nutrition status, and surgical history require multidisciplinary assessment. This is specialist territory—not self-requested prescribing. ### What documents speed up eligibility review? Bring recent HbA1c, fasting glucose, lipid panel, liver and kidney tests, thyroid history, weight trend records, prior diet programme documentation, medication list including supplements, and family history of thyroid cancer or pancreatitis. ### Does waist size alone qualify me for GLP-1? Waist above South Asian cut-offs (>90 cm men, >80 cm women) supports metabolic risk assessment alongside BMI but rarely qualifies alone without comorbidities or meeting ICMR BMI thresholds. Doctors integrate waist, labs, and history—not single measurements. ### Can I qualify with normal blood pressure and lipids? Yes for obesity pathway if BMI and lifestyle trial criteria are met—comorbidities strengthen but are not always mandatory at BMI ≥27.5. Diabetes pathway focuses on HbA1c and RSSDI cardiovascular criteria rather than requiring every comorbidity. ## References 1. [ICMR Expert Group. (2024). National Guidelines for Obesity Management in India.](https://www.icmr.gov.in/) 2. [RSSDI Clinical Practice Recommendations for Management of Type 2 Diabetes Mellitus (2023).](https://rssdi.in/) 3. [Joshi SR, et al. (2012). The Asian Indian Phenotype. JAPI, 60(Suppl), 5-8.](https://pubmed.ncbi.nlm.nih.gov/23165626/) 4. [WHO Expert Consultation. (2004). Appropriate BMI for Asian Populations.](https://pubmed.ncbi.nlm.nih.gov/14749299/) 5. [CDSCO. Drug Alerts and Advisories on GLP-1 Receptor Agonists.](https://cdsco.gov.in/) ## Related guides - [glp-1-explained-india](https://www.kesho.health/blog/glp-1-explained-india) · [MD](https://www.kesho.health/md/blog/glp-1-explained-india) - [how-to-talk-to-doctor-glp-1-india](https://www.kesho.health/blog/how-to-talk-to-doctor-glp-1-india) · [MD](https://www.kesho.health/md/blog/how-to-talk-to-doctor-glp-1-india) - [semaglutide-india-complete-guide](https://www.kesho.health/blog/semaglutide-india-complete-guide) · [MD](https://www.kesho.health/md/blog/semaglutide-india-complete-guide) - [glp-1-vs-bariatric-surgery-india](https://www.kesho.health/blog/glp-1-vs-bariatric-surgery-india) · [MD](https://www.kesho.health/md/blog/glp-1-vs-bariatric-surgery-india) --- *Kesho provides GLP-1 education only. We do not prescribe or sell medications. [Editorial policy](https://www.kesho.health/editorial-policy).*